Keeping children with congenital heart disease healthy

Journal of Pediatric Health Care

Volumn 25, Issue 6, 2011, Pages 373-378

  Woodward, Cathy S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Congenital heart disease; Mediastinitis; Pediatrics; Surgical site infection

Indexed keywords

CARDIOVASCULAR AGENT;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CLASSIFICATION; CONGENITAL HEART MALFORMATION; GROWTH; HEALTH PROMOTION; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFANT; NEWBORN; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CARDIOVASCULAR AGENTS; CHILD; CHILD, PRESCHOOL; GROWTH; HEALTH PROMOTION; HEART DEFECTS, CONGENITAL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN;

EID: 80054855467     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2011.03.007     Document Type: Article

References (20)

1. Al-Sukaiti N., Reid B., Lavi S., Al-Zaharani D., Atkinson A., Roifman C., Grunebaum E. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DeGeorge syndrome. [Letter to the Editor]. Journal of Allergy and Clinical Immunology 2010, August, 126:868-869.
2. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine and antibiotic prophylaxis. Pediatrics 2000, 106:362-366. American Academy of Pediatrics Committee on Infectious Diseases.
3. Morbidity and Mortality Weekly Report 2010, 59. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines, Retrieved from. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm.
4. Morbidity and Mortality Weekly Report 2010, 59(rr11). Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine, Retrieved from. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm?s_cid=rr5911a1_e.
5. Centers for Disease Control and Prevention. Updated recommendation for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. (2011, January 28). Morbidity and Mortality Weekly Report, 60(03). Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm.
6. Cohen M.S., Anderson R.H., Cohen M.I., Atz A.M., Fogel M., Gruber P., Weinberg P.M., et al. Controversies, genetics, diagnostic assessment, and outcomes relating to the heterotaxy syndrome. Cardiology in the Young 2007, 17(Suppl. 2):29-43.
7. Feltes T.F., Cabalka A.D., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., Connor E.M. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003, 143:532-540.
8. Hoffman J., Kaplan S. The incidence of congenital heart disease. The Journal of American college of Cardiology 2002, 39:1890-1900.
9. Jadcherla S., Vijayapal A., Leuthner S. Feeding abilities in neonates with congenital heart disease: a retrospective study. Journal of Perinatology 2009, 29:112-118.
10. Kliegman R., Behrman R., Jenson H., Stanton R. Kliegman: Nelson Textbook of Pediatrics 2007, Saunders Elsevier, Philadelphia, PA. 19th ed.
11. Kussman B.D., Wypij D., Laussen P.C., Soul J.S., Bellinger D.C., DiNardo J.A., Newburger J.W., et al. Relationship of interoperative cerebral oxygen saturation to neurodevelopmental outcome and brain magnetic resonance imaging at 1 year of age in infants undergoing biventricular repair. Circulation 2010, 109:245-254.
12. McDonald-McGinn, D. & Sullivan, K. (2011) Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore), 90, 1-18.
13. Perez E., Bokszczanin A., McDonald-McGinn D., Zackai E., Sullivan K. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome. Pediatrics 2003, 112:325-327.
14. Price V.E., Blanchette V.S., Ford-Jones E.L. The prevention and management of infections in children with asplenia or hyposplenia. Infectious Disease Clinics of North America 2007, 21:697-710.
15. Quartermain M.D., Ittenbach R.F., Flynn T.B., Gaynor J.W., Zhang X., Licht D.J., Wernovsky G., et al. Neuropsychological status in children after repair of acyanotic congenital heart disease. Pediatrics 2010, 126:351-359.
16. Shillingford A.J., Glanzman M.M., Ittenbach R.F., Clancy R.R., Gaynor J.W., Wernovsky G. Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 2008, 121:759-767.
17. Soul J.S., Robertson R.L., Wypij D., Bellinger D., Visconti K.J., duPlessis A.J., Newburger J.W., et al. Subtle hemorrhagic brain injury is associated with neurodevelopmental impairment in infants with repaired congenital heart disease. The Journal of Thoracic and Cardiovascular Surgery 2009, 138:374-381.
18. Takken T., Marieke H.P., Tachen A., Blank C., Hulzebos E.H., Strengers J.L., Helders P.J. Exercise limitation in patients with Fontan circulation: a review. Journal of Cardiovascular Medicine 2007, 8:775-781.
19. Weinberg S., Kern J., Weiss K., Ross G. Developmental screening of children diagnosed with congenital heart defects. Clinical Pediatrics 2001, 20:497-501.
20. Wilson W., Taubert K.A., Gewitz M., Lockhart P.B., Baddour L.M., Levison M., Durack D.T., et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 2007, 116:1736-1754.